[Spironolactone and thiabutazide in the treatment of essential hypertension (author's transl)].
The anti-hypertensive effect of spironolactone and thiabutazide was tested on 47 unselected patients with primary hypertension. They were divided into two groups according to the change in plasma-renin activity in response to furosemide administration: those with and those without response to stimulation, and sub-groups with low, normal or high plasma-renin activity (low renin hypertension; normal renin hypertension; high renin hypertension). During both 4-week treatment periods there was a distinct fall in systolic blood pressure, most marked in the patients without plasma renin stimulation (after spironolactone of about 26.2 mm Hg, after thiabutazide 29 mm Hg), the diastolic pressure fall being only slight in all groups (about 5-10 mm Hg). The plasma-renin activity and plasma-aldosterone concentration increased in all groups, after both spironolactone and thiabutazide three-to fourfold compared with the basal value,  even in patients without change in plasma-renin activity after furosemide injections. Serum sodium content decreased after administration of spironolactone, increasing again after subsequent thiabutazide administration. Serum potassium content increased after spironolactone, decreasing after thiabutazide. There was no significant difference between either individual groups or different treatment periods with spironolactone or thiabutazide as far as weight, urine volume or electrolyte excretion in 24-hour urine was concerned.
D000450:Aldosterone / Q000097:blood; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure; D001835:Body Weight; D002073:Butanes / Q000627:therapeutic use; D005260:Female; D005665:Furosemide / Q000494:pharmacology; D006801:Humans; D006852:Hydrochlorothiazide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006973:Hypertension / Q000145:classification / Q000188:drug therapy*; D009318:Natriuresis; D010919:Placebos; D011188:Potassium / Q000097:blood / Q000652:urine; D011247:Pregnancy; D012083:Renin / Q000097:blood; D012964:Sodium / Q000097:blood; D013148:Spironolactone / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000959:Antihypertensive Agents; D002073:Butanes; D010919:Placebos; D006852:Hydrochlorothiazide; D013148:Spironolactone; D000450:Aldosterone; D005665:Furosemide; D012964:Sodium; D012083:Renin; D011188:Potassium
Spironolacton und Thiabutazid bei der Behandlung der essentiellen Hypertonie